Search

Search Constraints

You searched for: Author/Creator Voit, Thomas

Search Results

1. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Issue 10101 (23rd September 2017)

2. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Issue 4 (October 2014)

3. CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy. Issue 1 (December 2015)

4. Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy. Issue 3 (26th May 2021)

5. Downregulation of miRNA-29, -23 and -21 in urine of Duchenne muscular dystrophy patients. (22nd March 2018)

6. Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Issue 1 (December 2017)

7. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. Issue 9979 (2nd May 2015)

8. GGPS1 Mutations Cause Muscular Dystrophy/Hearing Loss/Ovarian Insufficiency Syndrome. Issue 2 (18th June 2020)

9. International retrospective natural history study of LMNA-related congenital muscular dystrophy. Issue 3 (11th April 2021)

10. Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy. (15th March 2016)